Rinvoq Dosage
Generic name: upadacitinib 15mg
Dosage form: tablet, extended release
Drug class: Antirheumatics
Medically reviewed by Drugs.com. Last updated on Mar 26, 2025.
2.1 Recommended Evaluations and Immunizations Prior to Treatment Initiation
Prior to RINVOQ/RINVOQ LQ treatment initiation, consider performing the following evaluations:
● Active and latent tuberculosis (TB) infection evaluation - If positive, treat for TB prior to RINVOQ/RINVOQ LQ use.
● Viral hepatitis screening in accordance with clinical guidelines – RINVOQ/RINVOQ LQ initiation is not recommended in patients with active hepatitis B or hepatitis C.
● A complete blood count – RINVOQ/RINVOQ LQ initiation is not recommended in patients with an absolute lymphocyte count less than 500 cells/mm3, absolute neutrophil count less than 1000 cells/mm3, or hemoglobin level less than 8 g/dL.
● Baseline hepatic function: RINVOQ/RINVOQ LQ initiation is not recommended for patients with severe hepatic impairment (Child-Pugh C).
● Pregnancy Status: Verify the pregnancy status of females of reproductive potential prior to starting treatment.
Update immunizations according to current immunization guidelines.
2.2 Important Administration Instructions
● RINVOQ LQ oral solution is not substitutable with RINVOQ extended-release tablets.
● Changes between RINVOQ LQ oral solution and RINVOQ extended-release tablets should be made by the health care provider.
● RINVOQ/RINVOQ LQ should be taken orally with or without food.
● RINVOQ tablets should be swallowed whole. RINVOQ tablets should not be split, crushed, or chewed.
● RINVOQ LQ should be administered using the provided press-in bottle adapter and oral dosing syringe.
● RINVOQ LQ is dosed twice daily.
2.3 Recommended Dosage in Rheumatoid Arthritis
The recommended dosage of RINVOQ is 15 mg once daily.
2.4 Recommended Dosage in Psoriatic Arthritis
Pediatric Patients 2 to Less Than 18 Years of Age
The recommended dosage is based on body weight (Table 1).
| Patient Weight | RINVOQ LQ | RINVOQ |
| 10 kg to less than 20 kg | 3 mg (3 mL oral solution) twice daily | Not recommended |
| 20 kg to less than 30 kg | 4 mg (4 mL oral solution) twice daily | Not recommended |
| 30 kg and greater | 6 mg (6 mL oral solution) twice daily | 15 mg (one 15 mg tablet) once daily |
RINVOQ LQ oral solution is not substitutable with RINVOQ extended-release tablets. Changes between RINVOQ LQ oral solution and RINVOQ extended-release tablets should be made by the health care provider.
Adults 18 Years of Age and Older
The recommended dosage of RINVOQ is 15 mg once daily.
2.5 Recommended Dosage in Atopic Dermatitis
Pediatric Patients 12 Years of Age and Older Weighing at Least 40 kg and Adults Less Than 65 Years of Age
Initiate treatment with RINVOQ 15 mg once daily. If an adequate response is not achieved, consider increasing the dosage to 30 mg once daily. Discontinue RINVOQ if an adequate response is not achieved with the 30 mg dose. Use the lowest effective dose needed to maintain response.
Adults 65 Years of Age and Older
The recommended dosage of RINVOQ is 15 mg once daily.
2.6 Recommended Dosage in Ulcerative Colitis
Adult Patients: Induction
The recommended induction dosage of RINVOQ is 45 mg once daily for 8 weeks.
Adult Patients: Maintenance
The recommended dosage of RINVOQ for maintenance treatment is 15 mg once daily. A dosage of 30 mg once daily may be considered for patients with refractory, severe or extensive disease. Discontinue RINVOQ if an adequate therapeutic response is not achieved with the 30 mg dosage. Use the lowest effective dosage needed to maintain response.
2.7 Recommended Dosage in Crohn’s Disease
Adult Patients: Induction
The recommended induction dosage of RINVOQ is 45 mg once daily for 12 weeks.
Adult Patients: Maintenance
The recommended dosage of RINVOQ for maintenance treatment is 15 mg once daily. A dosage of 30 mg once daily may be considered for patients with refractory, severe or extensive disease. Discontinue RINVOQ if an adequate therapeutic response is not achieved with the 30 mg dosage. Use the lowest effective dosage needed to maintain response.
2.8 Recommended Dosage in Ankylosing Spondylitis
The recommended dosage of RINVOQ is 15 mg once daily.
2.9 Recommended Dosage in Non-radiographic Axial Spondyloarthritis
The recommended dosage of RINVOQ is 15 mg once daily.
2.10 Recommended Dosage in Polyarticular Juvenile Idiopathic Arthritis
The recommended dosage is based on body weight (Table 2).
| Patient Weight | RINVOQ LQ | RINVOQ |
| 10 kg to less than 20 kg | 3 mg (3 mL oral solution) twice daily | Not recommended |
| 20 kg to less than 30 kg | 4 mg (4 mL oral solution) twice daily | Not recommended |
| 30 kg and greater | 6 mg (6 mL oral solution) twice daily | 15 mg (one 15 mg tablet) once daily |
RINVOQ LQ oral solution is not substitutable with RINVOQ extended-release tablets. Changes between RINVOQ LQ oral solution and RINVOQ extended-release tablets should be made by the health care provider.
2.11 Recommended Dosage in Patients with Renal Impairment or Hepatic Impairment
Renal Impairment
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis, and pJIA:
● No dosage adjustment is needed for patients with mild, moderate, or severe renal impairment.
Atopic Dermatitis:
● For patients with severe renal impairment [estimated glomerular filtration rate (eGFR) 15 to < 30 mL/min/1.73m2] the recommended dosage of RINVOQ is 15 mg once daily.
● No dosage adjustment is needed for patients with mild or moderate renal impairment (eGFR ≥ 30 mL/min/1.73m2).
● RINVOQ is not recommended for use in patients with end stage renal disease (eGFR < 15 mL/min/1.73m2).
Ulcerative Colitis:
● For patients with severe renal impairment (eGFR 15 to < 30 mL/min/1.73m2), the recommended dosage of RINVOQ is:
• Induction: 30 mg once daily for 8 weeks
• Maintenance: 15 mg once daily
● No dosage adjustment is needed for patients with mild or moderate renal impairment (eGFR ≥ 30 mL/min/1.73m2).
● RINVOQ is not recommended for use in patients with end stage renal disease (eGFR < 15 mL/min/1.73m2).
Crohn’s Disease:
● For patients with severe renal impairment (eGFR 15 to < 30 mL/min/1.73m2), the recommended dosage of RINVOQ is: • Induction: 30 mg once daily for 12 weeks • Maintenance: 15 mg once daily
● No dosage adjustment is needed for patients with mild or moderate renal impairment (eGFR ≥ 30 mL/min/1.73m2).
● RINVOQ is not recommended for use in patients with end stage renal disease (eGFR < 15 mL/min/1.73m2).
Hepatic Impairment
RINVOQ/RINVOQ LQ is not recommended for use in patients with severe hepatic impairment (Child-Pugh C).
Rheumatoid Arthritis, Psoriatic Arthritis, Atopic Dermatitis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis, and pJIA:
No dosage adjustment is needed for patients with mild or moderate hepatic impairment (Child-Pugh A or B).
Ulcerative Colitis:
For patients with mild to moderate hepatic impairment (Child-Pugh A or B) the recommended dosage of RINVOQ is:
- Induction: 30 mg once daily for 8 weeks
- Maintenance: 15 mg once daily
Crohn’s Disease:
For patients with mild to moderate hepatic impairment (Child-Pugh A or B) the recommended dosage of RINVOQ is:
- Induction: 30 mg once daily for 12 weeks
- Maintenance: 15 mg once daily
2.12 Dosage Modifications Due to Drug Interactions
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis, and pJIA
No dosage adjustment is needed in patients receiving strong CYP3A4 inhibitors.
Atopic Dermatitis
The recommended dosage of RINVOQ in patients receiving strong CYP3A4 inhibitors is 15 mg once daily.
Ulcerative Colitis
The recommended dosage of RINVOQ in patients with ulcerative colitis receiving strong CYP3A4 inhibitors:
- Induction: 30 mg once daily for 8 weeks
- Maintenance: 15 mg once daily
Crohn’s Disease
The recommended dosage of RINVOQ in patients with Crohn’s disease receiving strong CYP3A4 inhibitors:
- Induction: 30 mg once daily for 12 weeks
- Maintenance: 15 mg once daily
2.13 Dosage Interruption
Infections
If a patient develops a serious infection, including serious opportunistic infection, interrupt RINVOQ/RINVOQ LQ treatment until the infection is controlled.
Laboratory Abnormalities
Interruption of dosing may be needed for management of laboratory abnormalities as described in Table 3.
| Laboratory Measure | Action |
| Absolute Neutrophil Count (ANC) | Interrupt treatment if ANC is less than 1000 cells/mm3; treatment may be restarted once ANC returns above this value |
| Absolute Lymphocyte Count (ALC) | Interrupt treatment if ALC is less than 500 cells/mm3; treatment may be restarted once ALC returns above this value |
| Hemoglobin (Hb) | Interrupt treatment if Hb is less than 8 g/dL; treatment may be restarted once Hb returns above this value |
| Hepatic transaminases | Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. |
Frequently asked questions
- What are the most common skin conditions? (with photos)
- What are the new drugs for rheumatoid arthritis (RA)?
- Rinvoq Copay Card: Do I qualify and how much can I save?
- What are JAK inhibitors and how do they work?
- Which JAK inhibitors are approved in the U.S?
- What is the MOA and half-life for Rinvoq?
- How long does Rinvoq stay in your system?
More about Rinvoq (upadacitinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (224)
- Drug images
- Latest FDA alerts (1)
- Side effects
- During pregnancy
- FDA approval history
- Drug class: antirheumatics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
